MRTX1719
Phase 1Small molecule
Bristol-Myers SquibbMRTX1719 is one of 50 small molecule programs targeting Mesothelioma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
53 competitors in Advanced Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 2
Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
T-Dxd
Daiichi SankyoPhase 3
Herceptin
RochePhase 2
Verzenio
Eli LillyPhase 2
Elunate
TakedaPhase 2
Torisel
PPrism Pharmaceuticals
Phase 2
Paraplatin
AAvyxa
Phase 2
Faslodex
FFresenius Kabi USA, LLC
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mesothelioma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MRTX1719. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company